Cognizin® Citicoline Effective for Improving Attention

May 16, 2011

New York, NY – Research conducted at the University of Utah Brain Institute revealed that individuals receiving Cognizin(R) Citicoline at a dose of 250 mg showed improved attention and a better ability to produce correct responses in performance testing. Participants who were administered either the 250 mg or the 500 mg dose of Cognizin produced nearly identical results when compared to the placebo group, confirming that 250 mg is an efficacious dose for producing improvements in attention.

hese new findings were presented by Erin McGlade, Ph.D., Research Fellow at the Brain Institute during a poster session titled "Improved Attentional Performance Following Citicoline Administration" at the 66th Annual Meeting of the Society of Biological Psychiatry in San Francisco on Thursday, May 12.

Subjects in this double-blind, placebo-controlled three-arm study to evaluate the effectiveness of Cognizin Citicoline on attentional function included 60 healthy women ages 40-60. Participants were divided into three groups of 20 and then completed a clinical screening visit, including a medical exam. After enrollment, each subject began supplementation with a daily oral dose of either 250 mg (low dose) or 500 mg (high dose) of Cognizin Citicoline or placebo for 28 days.

Participants were then evaluated with the Continuous Performance Test II (CPT-II), a measure sensitive to attentional function. Results after supplementation showed that individuals receiving either the low or high dose of Cognizin Citicoline produced fewer commission errors on the CPT-II compared to the placebo group. Specifically, individuals in the two Cognizin Citicoline supplemented groups made fewer errors when responding to non-target stimuli. These findings suggest improved attention when required to inhibit incorrect responses.

"Citicoline has been shown to have a variety of cognitive-enhancing and neuroregenerative properties in pre-clinical and clinical studies," noted Deborah Yurgelun-Todd, Ph.D., Director of the Cognitive Neuroimaging Laboratory at The Brain Institute at The University of Utah. "Our findings suggest that citicoline may mitigate the cognitive decline associated with normal aging and may ameliorate attentional deficits associated with psychiatric disorders."

More About Cognizin

Cognizin Citicoline is a natural, water-soluble brain health ingredient, and is a well-established part of the cognitive health category. Vast research indicates this safe and effective branded compound helps protect neural tissue from free radical damage. It also supports brain performance by enhancing metabolism and healthy activity. Unlike other single-action ingredients for brain health, Cognizin is multi-functional. It has been shown to benefit individuals affected by memory loss, mood/behavioral disorders, mild cognitive impairment and certain vision disorders. Cognizin is also highly stable, ultra-pure, allergen-free and has self-affirmed GRAS status, allowing it to be used in a variety of functional food and beverage applications, in addition to supplements. For more information on Cognizin visit www.cognizin.com. 

About Kyowa Hakko USA

Kyowa Hakko is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin(R) Citicoline, Hydrafend(TM) Hyaluronic Acid, Lumistor(R) L-Hydroxyproline, Setria(R) Glutathione, Kyowa CoQ10(TM) as well as Sustamine(TM) L-Alanyl-L-Glutamine.

# # #

Courtney Jacobs Morton
Integrated Marketing Group
P: 801-538-0777 x102
courtneym@imgbranding.com

---

‹ Back to 2011